A Phase 2 Study of Galunisertib (TGF-beta 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Kelley RK, Gane E, Assenat E, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva , Lahn M, Faivre S, Benhadji KA, Giannelli G, Siebler J (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Clinical and Translational Gastroenterology Lippincott, Williams & Wilkins / Nature Publishing Group

Book Volume: 10

DOI: 10.14309/ctg.0000000000000056

Abstract

INTRODUCTION: Inhibition of tumor growth factor-beta (TGF-beta) receptor type I potentiated the activity of sorafenib in preclinical models of hepatocellular carcinoma (HCC). Galunisertib is a small-molecule selective inhibitor of TGF-beta 1 receptor type I, which demonstrated activity in a phase 2 trial as second-line HCC treatment.

Authors with CRIS profile

Jürgen Siebler Professur für Hepatologie

Involved external institutions

Centre Hospitalier Universitaire de Caen FR France (FR) Hospices Civils de Lyon (CHU) FR France (FR) Universitätsmedizin der Johannes Gutenberg-Universität Mainz DE Germany (DE) Auckland City Hospital NZ New Zealand (NZ) Eli Lilly and Company US United States (USA) (US) Beaujon Hospital / Hôpital Beaujon FR France (FR) Centre Hospitalier Universitaire de Montpellier (CHU/CHRU MTP) FR France (FR) University of California San Francisco (UCSF) US United States (USA) (US)

How to cite

APA:

Kelley, R.K., Gane, E., Assenat, E., Galle, P.R., Merle, P., Hourmand, I.O.,... Siebler, J. (2019). A Phase 2 Study of Galunisertib (TGF-beta 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clinical and Translational Gastroenterology, 10. https://dx.doi.org/10.14309/ctg.0000000000000056

MLA:

Kelley, R. K., et al. "A Phase 2 Study of Galunisertib (TGF-beta 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma." Clinical and Translational Gastroenterology 10 (2019).

BibTeX: Download